Yehuda Handelsman to Dipeptidyl-Peptidase IV Inhibitors
This is a "connection" page, showing publications Yehuda Handelsman has written about Dipeptidyl-Peptidase IV Inhibitors.
Connection Strength
0.241
-
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy. Curr Med Res Opin. 2017 10; 33(10):1861-1868.
Score: 0.139
-
Treating diabetes with incretin hormones - clinical experience. Pediatr Endocrinol Rev. 2008 Jun; 5(4):897-903.
Score: 0.074
-
Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-na?ve patients with type 2 diabetes. Diabetes Obes Metab. 2014 Sep; 16(9):869-72.
Score: 0.028